Cerity Partners
RGC icon

Cerity Partners’s Regencell Bioscience RGC Stock Holding History

Cerity Partners’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$801K Buy
+128,706
New +$745K ﹤0.01% 2161

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Savant Capital
Savant Capital Rockford, Illinois $35B AUM 15.18% 1-Year Est. Return
CIBC Asset Management
CIBC Asset Management Toronto, Ontario, Canada $47B AUM 34.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
Larson Financial Group
Larson Financial Group St Louis, Missouri $4.11B AUM 23.62% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Cerity Partners's RGC Position: Q3 2026 in Review

Cerity Partners opened a new position in Regencell Bioscience (RGC) in Q3 2026: 128,706 shares worth $801K. The stake represents ﹤0.01% of the portfolio and ranks #2161 among its holdings.

24 funds tracked by Wall St. Rank hold RGC as of Q3 2026.

  • Cerity Partners held 128,706 shares of Regencell Bioscience worth $801K as of Q3 2026.
  • Regencell Bioscience was a new Cerity Partners position in Q3 2026.
  • Regencell Bioscience made up ﹤0.01% of Cerity Partners's portfolio in Q3 2026, its #2161 holding.
  • 24 funds tracked by Wall St. Rank held Regencell Bioscience as of Q3 2026.

Based on Cerity Partners's 13F filing for Q3 2026, filed 13 Nov 2026.